早期大脑粉样β的积累和高代谢与加速大脑缩之前的微妙认知缺陷有关
Aftab Bakhtiari1,2,3,4, Krisztina Benedek5, Ian Law6
1Functional Imaging Unit, Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet Glostrup, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. aftab.bakhtiari@sund.ku.dk.
GeroScience
|December 15, 2023
概括
大脑中早期的粉样β (Aβ) 积累与微妙的记忆力下降有关,先于其他阿尔茨海默病 (AD) 标志物,如低代谢或缩. 这表明Aβ积累在早期与年龄相关的认知功能障碍中起作用.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 积累,导致一连串的有害影响.
- 这一连串的确切时间和因果关系,包括大脑低代谢,大脑缩和认知衰退,仍然不完全理解.
- 研究早期Aβ积累对于了解AD和与年龄相关的认知功能障碍的开始至关重要.
研究的目的:
- 为了检查早期的粉样β (Aβ) 积累是否影响大脑葡萄糖代谢,缩率和明显的神经退行之前与年龄相关的认知衰退.
- 建立Aβ沉积和随后的病理变化和认知缺陷之间的时间关系.
主要方法:
- 使用[11C]匹兹堡化合物-B (PiB) 和[18F]氧糖 (FDG) 的正子发射断层扫描 (PET) 来评估分别在70名和76名参与者的Aβ和葡萄糖代谢.
- 使用连续磁共振成像 (MRI) 扫描计算的大脑缩率,覆盖长达10年的时间.
- 通过5-10年进行的神经生理学测试评估认知能力下降.
主要成果:
- 在AD关键区域中Aβ积累较高与视觉记忆下降较大相关 (p=0.023).
- Aβ积累与大脑缩率没有相关性.
- 在AD易受影响的区域中,大脑葡萄糖代谢的增加与口头记忆表现的恶化相关 (p=0.040).
结论:
- 粉样β (Aβ) 在与阿尔茨海默病相关的大脑区域的积累与微妙的认知缺陷有关,在低代谢或加速大脑缩之前观察到.
- 这些发现表明,Aβ积累是与年龄相关的认知功能障碍的早期贡献者.
- 与记忆力下降相关的超能代谢可能代表神经元功能障碍的补偿机制.
相关概念视频
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


